Sanofi and GlaxoSmithKline are restarting clinical development of their COVID-19 vaccine, which was delayed after hitting a snag late last year. In December interim phase 1/2 trial results showed ...

In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former ...

Electronic reminders to encourage older adults in Denmark to get vaccinated against flu may have unintentionally lowered ...

Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former executive from the UK big pharma to advance its candidate amezosvatein. The ...

Sanofi’s CEO Paul Hudson has courted controversy by saying the French pharma’s potential COVID-19 vaccine will likely be delivered to the US government first should it succeed in clinical trials.

Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors ...

Vaccines Market Growth, Share Herpes simplex virus (HSV) is known for causing herpes infection. This is majorly ...

The White House is reportedly considering former U.S. Rep. Michael Burgess (R-Texas) as its nominee to head the CDC. Burgess, ...

The updated mRNA-1273.815 COVID-19 vaccine was significantly protective against hospitalization and medically attended outcomes among adults in the United States.